Right ventricular expression of NT-proBNP adds predictive value to REVEAL score in patients with pulmonary arterial hypertension

doi:10.1002/ehf2.13410

Chia Nan University of Pharmacy & Science Institutional Repository > 智慧生活學院 > 醫務管理系(所) > 期刊論文 > Item 310902800/34426

請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34426

標題:	Right ventricular expression of NT-proBNP adds predictive value to REVEAL score in patients with pulmonary arterial hypertension
作者:	Chang, Wei-Ting Shih, Jhih-Yuan Hong, Chon-Seng Lin, Yu-Wen Chen, Yi-Chen Ho, Chung-Han Chen, Zhih-Cherng Roan, Jun-Neng Hsu, Chih-Hsin
貢獻者:	Chi Mei Med Ctr, Div Cardiol, Dept Internal Med Southern Taiwan Univ Sci & Technol, Dept Biotechnol Natl Cheng Kung Univ, Inst Clin Med, Coll Med Chi Mei Med Ctr, Dept Med Res Chia Nan Univ Pharm & Sci, Dept Hosp & Hlth Care Adm Natl Cheng Kung Univ Hosp, Div Cardiovasc Surg, Dept Surg Natl Cheng Kung Univ, Coll Med Natl Cheng Kung Univ, Med Device Innovat Ctr Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Dept Internal Med, Coll Med Natl Cheng Kung Univ Hosp, Dou Liou Branch, Dept Internal Med Kaohsiung Med Univ, Coll Med, Dept Resp Therapy
關鍵字:	NT-proBNP RV expression HF hospitalization Group I PAH
日期:	2021
上傳時間:	2023-11-11 11:52:05 (UTC+8)
出版者:	WILEY PERIODICALS, INC
摘要:	Aims The Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) risk scores differentiate survivals in patients with pulmonary arterial hypertension (PAH). However, measurements of N-terminal pro B-type natriuretic peptide (NT-proBNP) in the peripheral blood may not adequately reflect early-stage decompensated heart failure (HF). Given that right heart catheterization (RHC) can facilitate measurements of intracardiac NT-proBNP, in this study our aim was to evaluate the predictive role of right ventricular (RV) NT-proBNP measurements in patients with PAH. Methods and results We prospectively collected intracardiac blood samples for NT-proBNP measurements from patients diagnosed with World Health Organization Group I PAH during RHC. Clinical information including the aetiology of PAH (idiopathic, connective tissue disease, or congenital heart disease) and REVEAL scores were recorded. The primary endpoint was hospitalization for decompensated HF; median duration of follow-up was 28 months. Among the 62 patients evaluated, 12 reached the designated endpoint. REVEAL risk scores were higher among patients hospitalized for HF. We detected no significant differences in plasma NT-proBNP levels in peripheral circulation, in the right atrium, or in pulmonary arterial blood; however, significantly higher levels of NT-proBNP were detected in the RV in patients diagnosed with PAH. RV NT-proBNP was a sensitive predictor (cut-off value 1500 pg/mL) of subsequent hospitalization for HF. Our findings indicate that RV NT-proBNP levels add predictive value to REVEAL scores with respect to future hospitalization due to HF. Conclusions Right ventricular NT-proBNP levels combined with REVEAL 2.0 could predict the development of subsequent HF in patients with PAH and may be a potential biomarker.
關聯:	ESC HEART FAIL, v.8, n.4, pp.3082-3092
顯示於類別:	[醫務管理系(所)] 期刊論文

文件中的檔案:

檔案	描述	大小	格式	瀏覽次數
ehf2.13410.pdf		4820Kb	Adobe PDF	102	檢視/開啟
index.html		0Kb	HTML	248	檢視/開啟

在CNU IR中所有的資料項目都受到原著作權保護.

TAIR相關文章

資料載入中.....